You are here
Norethindrone, Generic Equivalent of Ortho-Micronor, Now Available
CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has launched JOLIVETTE™ (norethindrone tablets), a brand equivalent of the oral contraceptive Ortho-Micronor®, marketed by Ortho-McNeil Pharmaceutical, Inc. In 2002, Ortho-Micronor® had annual sales of approximately $51 million. JOLIVETTE™ is indicated for the prevention of pregnancy.
"Watson is known for having the broadest oral contraceptive portfolio in the pharmaceutical industry," said Joseph Papa, Watson's President and Chief Operating Officer. "The launch of JOLIVETTE™ marks our fourth oral contraceptive launch in 2003, bringing Watson's oral contraceptive product offerings to 15 products and 23 strengths."